arXiv subjects

Larry Han

Publications and source records attributed to Larry Han.

16 recordsLinked to original sources

arXiv2026

Towards Best Practices for Covariate Adjustment in Regulatory Trials: From Fixed to Data-Adaptive Approaches

While randomization justifies the use of unadjusted effect estimators in randomized trials, there is growing interest in covariate adjustment to improve precision. Adjusting for baseline variables that are prognostic of the outcome can reduce estimator variance, resulting in narrower confidence intervals and increased statistical power. Recent guidance by the U.S. Food and Drug Administration supports fixed adjustment for prognostic covariates using parametric regression models. However, this guidance does not address more flexible approaches using data-adaptive or machine learning methods. We offer our perspectives on covariate adjustment to improve analytic precision. We focus on estimating the average effect for the target population in trials with minimal outcome missingness. We provide a non-technical overview of effect estimators that are unadjusted and effect estimators using fixed versus data-adaptive adjustment. We offer practical suggestions for conducting adjusted analyses that are data-adaptive, fully pre-specified, transparently and reproducibly implemented, robust to model misspecification, and guaranteed to improve precision relative to unadjusted analyses --- all while preserving statistical validity and the causal effect of interest. We hope that sharing our perspectives will foster broader discussion and eventual acceptance of principled, pre-specified, data-adaptive covariate adjustment in randomized trials.

stat.ME↗

arXiv2026

History-Aware Conformal Prediction Sets for Censored Time-to-Event Outcomes

Existing conformal prediction methods for time-to-event outcomes leverage only baseline covariates, producing prediction intervals that are insufficiently informative to facilitate decision making. We propose History-Aware Prediction Sets (HAPS), a conformal framework that constructs prediction sets for individual event times using covariate histories observed up to a decision time, targeting coverage among individuals who have survived to this time. HAPS handles right censoring adjusted for time-varying confounders via inverse probability of censoring weighting. When the censoring weights are consistently estimated, it achieves PAAC (probably asymptotically approximately correct) coverage among survivors. We further propose two doubly robust extensions of HAPS to weaken reliance on consistent estimation of the censoring distribution. In simulations, HAPS and its extensions reduce median prediction interval length by up to 75\% relative to baseline comparators while maintaining close to nominal coverage. On two public benchmark data sets, HAPS reduces the median interval length by up to 60\% for predictions at year 5, compared to the baseline comparators.

stat.ME↗

arXiv2026

Considerations for the Integration of Randomized Controlled Trials and Real-World Data

As clinical decision-making increasingly moves toward individualized and context-specific treatment recommendations, reliance on any single evidence source, randomized or observational, may be insufficient. Principled integration of randomized controlled trials and real-world data, grounded in explicit causal frameworks, offers a path toward evidence that is both internally credible and externally relevant. In this article, we describe distinct objectives for the integration of randomized controlled trials and real-world data and discuss how these objectives shape key design and analytic considerations, illustrating the resulting choices through example estimands. We highlight practical issues that commonly arise in applied settings, including data relevance and curation, cross-source comparability, estimand specification, and sensitivity analysis. We aim for this article to help readers evaluate and implement principled approaches to integrating randomized controlled trials and real-world data in ways that can support more reliable treatment recommendations while maintaining regulatory-grade evidentiary standards.

stat.ME↗

arXiv2025

Targeted Data Fusion for Region-Specific Survival Effects in the AMP HIV Prevention Trials

The Antibody Mediated Prevention (AMP) trials opened a new scientific frontier by showing that passively administered monoclonal broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition. Conducted across multiple geographic regions, including the United States, Brazil, Peru, Switzerland, and sub-Saharan Africa, the AMP trials revealed substantial regional heterogeneity in treatment efficacy. These differences, together with privacy and regulatory limits on central data pooling, call for methods that borrow strength across regions without sharing individual-level data. To estimate region- and treatment-specific survival curves under distributional heterogeneity, we develop a federated learning approach that combines site-specific estimators via an L1-regularized criterion that downweights data sources not aligned with the target. We further extend the framework to a general class of causal contrasts, including the risk difference (RD), survival ratio (SR), and restricted mean survival time (RMST) difference. Through extensive simulations and an analysis of the AMP trials under different target populations, we show that the proposed approach provides privacy-preserving, region-adaptive inference with improved precision.

stat.ME↗

arXiv2025

COADVISE: Covariate Adjustment with Variable Selection in Randomized Controlled Trials

Adjusting for covariates in randomized controlled trials can enhance the credibility and efficiency of treatment effect estimation. However, handling numerous covariates and their complex (non-linear) transformations poses a challenge. Motivated by the case study of the Best Apnea Interventions for Research (BestAIR) trial data from the National Sleep Research Resource (NSRR), where the number of covariates (p=114) is comparable to the sample size (N=196), we propose a principled Covariate Adjustment with Variable Selection (COADVISE) framework. COADVISE enables variable selection for covariates most relevant to the outcome while accommodating both linear and nonlinear adjustments. This framework ensures consistent estimates with improved efficiency over unadjusted estimators and provides robust variance estimation, even under outcome model misspecification. We demonstrate efficiency gains through theoretical analysis, extensive simulations, and a re-analysis of the BestAIR trial data to compare alternative variable selection strategies, offering cautionary recommendations. A user-friendly R package, Coadvise, is available to facilitate practical implementation.

stat.ME↗

arXiv2024

On the Role of Surrogates in Conformal Inference of Individual Causal Effects

Learning the Individual Treatment Effect (ITE) is essential for personalized decision-making, yet causal inference has traditionally focused on aggregated treatment effects. While integrating conformal prediction with causal inference can provide valid uncertainty quantification for ITEs, the resulting prediction intervals are often excessively wide, limiting their practical utility. To address this limitation, we introduce \underline{S}urrogate-assisted \underline{C}onformal \underline{I}nference for \underline{E}fficient I\underline{N}dividual \underline{C}ausal \underline{E}ffects (SCIENCE), a framework designed to construct more efficient prediction intervals for ITEs. SCIENCE accommodates the covariate shifts between source data and target data and applies to various data configurations, including semi-supervised and surrogate-assisted semi-supervised learning. Leveraging semi-parametric efficiency theory, SCIENCE produces rate double-robust prediction intervals under mild rate convergence conditions, permitting the use of flexible non-parametric models to estimate nuisance functions. We quantify efficiency gains by comparing semi-parametric efficiency bounds with and without the surrogates. Simulation studies demonstrate that our surrogate-assisted intervals offer substantial efficiency improvements over existing methods while maintaining valid group-conditional coverage. Applied to the phase 3 Moderna COVE COVID-19 vaccine trial, SCIENCE illustrates how multiple surrogate markers can be leveraged to generate more efficient prediction intervals.

stat.ME↗

arXiv2024

Bounding causal effects with an unknown mixture of informative and non-informative missingness

In experimental and observational data settings, researchers often have limited knowledge of the reasons for missing outcomes. To address this uncertainty, we propose bounds on causal effects for missing outcomes, accommodating the scenario where missingness is an unobserved mixture of informative and non-informative components. Within this mixed missingness framework, we explore several assumptions to derive bounds on causal effects, including bounds expressed as a function of user-specified sensitivity parameters. We develop influence-function based estimators of these bounds to enable flexible, non-parametric, and machine learning based estimation, achieving root-n convergence rates and asymptotic normality under relatively mild conditions. We further consider the identification and estimation of bounds for other causal quantities that remain meaningful when informative missingness reflects a competing outcome, such as death. We conduct simulation studies and illustrate our methodology with a study on the causal effect of antipsychotic drugs on diabetes risk using a health insurance dataset.

stat.ME↗

arXiv2024

A Surrogate Endpoint Based Provisional Approval Causal Roadmap

For many rare diseases with no approved preventive interventions, promising interventions exist, yet it has been difficult to conduct a pivotal phase 3 trial that could provide direct evidence demonstrating a beneficial effect on the target disease outcome. When a promising putative surrogate endpoint(s) for the target outcome is available, surrogate-based provisional approval of an intervention may be pursued. We apply the Causal Roadmap rubric to define a surrogate endpoint based provisional approval causal roadmap, which combines observational study data that estimates the relationship between the putative surrogate and the target outcome, with a phase 3 surrogate endpoint study that collects the same data but is very under-powered to assess the treatment effect (TE) on the target outcome. The objective is conservative estimation/inference for the TE with an estimated lower uncertainty bound that allows (through two bias functions) for an imperfect surrogate and imperfect transport of the conditional target outcome risk in the untreated between the observational and phase 3 studies. Two estimators of TE (plug-in, nonparametric efficient one-step) with corresponding inference procedures are developed. Finite-sample performance of the plug-in estimator is evaluated in two simulation studies, with R code provided. The roadmap is illustrated with contemporary Group B Streptococcus vaccine development.

stat.ME↗

arXiv2024

Multi-Source Conformal Inference Under Distribution Shift

Recent years have experienced increasing utilization of complex machine learning models across multiple sources of data to inform more generalizable decision-making. However, distribution shifts across data sources and privacy concerns related to sharing individual-level data, coupled with a lack of uncertainty quantification from machine learning predictions, make it challenging to achieve valid inferences in multi-source environments. In this paper, we consider the problem of obtaining distribution-free prediction intervals for a target population, leveraging multiple potentially biased data sources. We derive the efficient influence functions for the quantiles of unobserved outcomes in the target and source populations, and show that one can incorporate machine learning prediction algorithms in the estimation of nuisance functions while still achieving parametric rates of convergence to nominal coverage probabilities. Moreover, when conditional outcome invariance is violated, we propose a data-adaptive strategy to upweight informative data sources for efficiency gain and downweight non-informative data sources for bias reduction. We highlight the robustness and efficiency of our proposals for a variety of conformal scores and data-generating mechanisms via extensive synthetic experiments. Hospital length of stay prediction intervals for pediatric patients undergoing a high-risk cardiac surgical procedure between 2016-2022 in the U.S. illustrate the utility of our methodology.

stat.ME↗

arXiv2024

A Transfer Learning Causal Approach to Evaluate Racial/Ethnic and Geographic Variation in Outcomes Following Congenital Heart Surgery

Congenital heart defects (CHD) are the most prevalent birth defects in the United States and surgical outcomes vary considerably across the country. The outcomes of treatment for CHD differ for specific patient subgroups, with non-Hispanic Black and Hispanic populations experiencing higher rates of mortality and morbidity. A valid comparison of outcomes within racial/ethnic subgroups is difficult given large differences in case-mix and small subgroup sizes. We propose a causal inference framework for outcome assessment and leverage advances in transfer learning to incorporate data from both target and source populations to help estimate causal effects while accounting for different sources of risk factor and outcome differences across populations. Using the Society of Thoracic Surgeons' Congenital Heart Surgery Database (STS-CHSD), we focus on a national cohort of patients undergoing the Norwood operation from 2016-2022 to assess operative mortality and morbidity outcomes across U.S. geographic regions by race/ethnicity. We find racial and ethnic outcome differences after controlling for potential confounding factors. While geography does not have a causal effect on outcomes for non-Hispanic Caucasian patients, non-Hispanic Black patients experience wide variability in outcomes with estimated 30-day mortality ranging from 5.9% (standard error 2.2%) to 21.6% (4.4%) across U.S. regions.

stat.ME↗

arXiv2023

Multiply Robust Federated Estimation of Targeted Average Treatment Effects

Federated or multi-site studies have distinct advantages over single-site studies, including increased generalizability, the ability to study underrepresented populations, and the opportunity to study rare exposures and outcomes. However, these studies are challenging due to the need to preserve the privacy of each individual's data and the heterogeneity in their covariate distributions. We propose a novel federated approach to derive valid causal inferences for a target population using multi-site data. We adjust for covariate shift and covariate mismatch between sites by developing multiply-robust and privacy-preserving nuisance function estimation. Our methodology incorporates transfer learning to estimate ensemble weights to combine information from source sites. We show that these learned weights are efficient and optimal under different scenarios. We showcase the finite sample advantages of our approach in terms of efficiency and robustness compared to existing approaches.

stat.ML↗

arXiv2023

Robust Inference for Federated Meta-Learning

Synthesizing information from multiple data sources is critical to ensure knowledge generalizability. Integrative analysis of multi-source data is challenging due to the heterogeneity across sources and data-sharing constraints due to privacy concerns. In this paper, we consider a general robust inference framework for federated meta-learning of data from multiple sites, enabling statistical inference for the prevailing model, defined as the one matching the majority of the sites. Statistical inference for the prevailing model is challenging since it requires a data-adaptive mechanism to select eligible sites and subsequently account for the selection uncertainty. We propose a novel sampling method to address the additional variation arising from the selection. Our devised CI construction does not require sites to share individual-level data and is shown to be valid without requiring the selection of eligible sites to be error-free. The proposed robust inference for federated meta-learning (RIFL) methodology is broadly applicable and illustrated with three inference problems: aggregation of parametric models, high-dimensional prediction models, and inference for average treatment effects. We use RIFL to perform federated learning of mortality risk for patients hospitalized with COVID-19 using real-world EHR data from 16 healthcare centers representing 275 hospitals across four countries.

stat.ME↗

arXiv2022

Sensitivity Analyses of Clinical Trial Designs: Selecting Scenarios and Summarizing Operating Characteristics

The use of simulation-based sensitivity analyses is fundamental to evaluate and compare candidate designs for future clinical trials. In this context, sensitivity analyses are especially useful to assess the dependence of important design operating characteristics (OCs) with respect to various unknown parameters (UPs). Typical examples of OCs include the likelihood of detecting treatment effects and the average study duration, which depend on UPs that are not known until after the onset of the clinical study, such as the distributions of the primary outcomes and patient profiles. Two crucial components of sensitivity analyses are (i) the choice of a set of plausible simulation scenarios $\{\boldsymbol{\theta}_1,...,\boldsymbol{\theta}_K\}$ and (ii) the list of OCs of interest. We propose a new approach to choose the set of scenarios for inclusion in design sensitivity analyses. Our approach balances the need for simplicity and interpretability of OCs computed across several scenarios with the need to faithfully summarize -- through simulations -- how the OCs vary across all plausible values of the UPs. Our proposal also supports the selection of the number of simulation scenarios to be included in the final sensitivity analysis report. To achieve these goals, we minimize a loss function $\mathcal{L}(\boldsymbol{\theta}_1,...,\boldsymbol{\theta}_K)$ that formalizes whether a specific set of $K$ sensitivity scenarios $\{\boldsymbol{\theta}_1,...,\boldsymbol{\theta}_K\}$ is adequate to summarize how the OCs of the trial design vary across all plausible values of the UPs. Then, we use optimization techniques to select the best set of simulation scenarios to exemplify the OCs of the trial design.

stat.ME↗

arXiv2022

Privacy-Preserving, Communication-Efficient, and Target-Flexible Hospital Quality Measurement

Integrating information from multiple data sources can enable more precise, timely, and generalizable decisions. However, it is challenging to make valid causal inferences using observational data from multiple data sources. For example, in healthcare, learning from electronic health records contained in different hospitals is desirable but difficult due to heterogeneity in patient case mix, differences in treatment guidelines, and data privacy regulations that preclude individual patient data from being pooled. Motivated to overcome these issues, we develop a federated causal inference framework. We devise a doubly robust estimator of the mean potential outcome in a target population and show that it is consistent even when some models are misspecified. To enable real-world use, our proposed algorithm is privacy-preserving (requiring only summary statistics to be shared between hospitals) and communication-efficient (requiring only one round of communication between hospitals). We implement our causal estimation and inference procedure to investigate the quality of hospital care provided by a diverse set of 51 candidate Cardiac Centers of Excellence, as measured by 30-day mortality and length of stay for acute myocardial infarction (AMI) patients. We find that our proposed federated global estimator improves the precision of treatment effect estimates by 59% to 91% compared to using data from the target hospital alone. This precision gain results in qualitatively different conclusions about the estimated effect of percutaneous coronary intervention (PCI) compared to medical management (MM) in 63% (32 of 51) of hospitals. We find that hospitals rarely excel in both PCI and MM, which highlights the importance of assessing performance on specific treatment regimens.

stat.ME↗

arXiv2021

Federated Adaptive Causal Estimation (FACE) of Target Treatment Effects

Federated learning of causal estimands may greatly improve estimation efficiency by leveraging data from multiple study sites, but robustness to heterogeneity and model misspecifications is vital for ensuring validity. We develop a Federated Adaptive Causal Estimation (FACE) framework to incorporate heterogeneous data from multiple sites to provide treatment effect estimation and inference for a flexibly specified target population of interest. FACE accounts for site-level heterogeneity in the distribution of covariates through density ratio weighting. To safely incorporate source sites and avoid negative transfer, we introduce an adaptive weighting procedure via a penalized regression, which achieves both consistency and optimal efficiency. Our strategy is communication-efficient and privacy-preserving, allowing participating sites to share summary statistics only once with other sites. We conduct both theoretical and numerical evaluations of FACE and apply it to conduct a comparative effectiveness study of BNT162b2 (Pfizer) and mRNA-1273 (Moderna) vaccines on COVID-19 outcomes in U.S. veterans using electronic health records from five VA regional sites. We show that compared to traditional methods, FACE meaningfully increases the precision of treatment effect estimates, with reductions in standard errors ranging from $26\%$ to $67\%$.

stat.ME↗

arXiv2021

On the Evaluation of Surrogate Markers in Real World Data Settings

Shortcomings of randomized clinical trials are pronounced in urgent health crises, when rapid identification of effective treatments is critical. Leveraging short-term surrogates in real-world data (RWD) can guide policymakers evaluating new treatments. In this paper, we develop novel estimators for the proportion of treatment effect (PTE) on the true outcome explained by a surrogate in RWD settings. We propose inverse probability weighted and doubly robust (DR) estimators of an optimal transformation of the surrogate and PTE by semi-nonparametrically modeling the relationship between the true outcome and surrogate given baseline covariates. We show that our estimators are consistent and asymptotically normal, and the DR estimator is consistent when either the propensity score model or outcome regression model is correctly specified. We compare our proposed estimators to existing estimators and show a reduction in bias and gains in efficiency through simulations. We illustrate the utility of our method in obtaining an interpretable PTE by conducting a cross-trial comparison of two biologic therapies for ulcerative colitis.

stat.ME↗